Regeneron Pharmaceuticals (REGN) has delivered a performance over the past twelve months, rewarding shareholders with a 45.7% return from November 3, 2025 to November 4, 2026, significantly outpacing the 13.5% gain of the S&P 500. However, beneath the surface of this strong equity appreciation lies a structural vulnerability centered on its retinal franchise. As the company manages a transition toward newer formulations, the market is beginning to weigh the sustainability of its growth against the encroaching threat of biosimilar competition.
-
The Bottom Line:
- The Alpha Metric: A 1% year-over-year decline in combined U.S. sales for EYLEA and EYLEA HD during fiscal Q3 2026 signals a critical inflection point for the company’s primary revenue engine.
- Valuation Disconnect: Despite the stock trading close to the top of its past year, it remains priced at 19.6 times the past twelve months’ profit, trailing the S&P 500 average of 22.8, reflecting investor caution regarding future margin compression.
- Strategic Pivot: With EYLEA revenue under pressure, Regeneron is increasingly reliant on Sanofi collaboration revenue—which hit an all-time high of $2.7 billion in Q3—and the pending FDA approval of a prefilled syringe for EYLEA HD to offset losses.
The Erosion of the Retinal Franchise
The core of the issue resides in the EYLEA product line, which accounted for 31% of Regeneron’s total revenue in fiscal 2025. EYLEA sales dropped by about $2 billion to $2.75 billion during that period. While the higher-dose EYLEA HD has seen a 36.3% growth trajectory, management acknowledged on the October 30, 2026, call that this growth is being partially neutralized by persistent pricing pressure. The market is now dealing with the reality of a product facing increasing competition from additional 2-milligram biosimilar launches.
Tracking Combined Sales Figures for Long-Term Portfolio Risk
Investors holding Regeneron through broad-market index funds are effectively exposed to this competitive risk, which is why monitoring the combined U.S. sales figures—due for release in January 2027—is essential for assessing long-term portfolio risk.
Smart Money Tracking Regulatory Hurdles
Institutional sentiment remains split between the company’s historical success and the looming threats to its top line. While the stock currently trades just 4.4% below its highest close of the past 365 days, the valuation discount suggests that the “smart money” is not yet convinced that EYLEA HD can fully absorb the revenue vacuum left by the original EYLEA. The company is leaning heavily on the U.S. Food and Drug Administration to approve the prefilled syringe for EYLEA HD before the end of the year. This hardware innovation is intended to help sustain EYLEA HD’s growth in 2027 and beyond, yet the market remains wary of whether such tactical moves can sustain growth if biosimilar penetration accelerates faster than anticipated.
The Path Toward 2027
Regeneron’s ability to pivot its revenue model away from the original EYLEA will define its performance in the coming fiscal year. The reliance on collaboration revenue from Sanofi, its partner on Dupixent, has provided a necessary buffer for the bottom line. However, the market is looking for evidence that the transition to EYLEA HD will stabilize the retinal franchise. Investors should look to the Regeneron Investor Relations portal for the upcoming January 2027 disclosure, as this will provide the definitive data on whether the combined U.S. sales decline of 1% was a temporary blip or the beginning of a sustained trend.
Disclaimer: The information provided in this article is for educational and market analysis purposes only and does not constitute financial, investment, or legal advice. Always consult with a certified financial professional before making investment decisions.
